Publikationsliste
<< Tilbage
« Forrige
1
2
3
4
5
6
Næste »
33. Seidel C, Lenhoff S, Brabrand S, Anderson G, Standal T, Lanng-Nielsen J, Turesson I, Borset M, Waage A, For the Nordic Myeloma Study Group: Hepatocyte growth factor in myeloma patients treated with high-dose chemotherapy. Br J Haematol 2002; 119: 672-676.
34. Standal T, Borset M, Lenhoff S, Wisloff F, Stordal B, Sundan A, Waage A, Seidel C. Serum insulin-like growth factor is not elevated in patients with multiple myeloma but is still a prognostic factor. Blood 2002; 100: 3925-3929.
35. Erikson T, Høglund P, Turesson I, Waage A, don BR, Wu J, Kaysen GA. Pharmacokinetics of thalidomide during dialysis and in patients with impaired renal function. J Pharm Pharmacol 2003; 55: 1701-06.
36. Brenne AT, Romstad LH, Gimsing P, Juliusson G, Turesson I, Romundstad P, Borset M, Sudan A, Waage A. A low serum level of soluble tumour necrosis factor receptor p55 predicts response to thalidomide in advanced multiple myeloma. Haematologica 2004; 89:552-557.
37. Standahl T, Hjorth-Hansen H, Rasmussen T, Dahl IM, Lenhoff S, Brenne AT, Seidel C, Baykov V, Waage A, Börset M, Sundan A, Hjertner Ö: Osteopontin is an adhesive factor for myeloma cells and is found in increased levels in plasma from patients with multiple myeloma. Haematologica 2004; 89:174-182.
38. Waage A, Turesson I, Juliusson G, Gimsing P, Gulbrandsen N, Wislöff F, Eriksson T, Westin J, Lenhoff S, Lanng Nielsen J, Hjorth M, for the Nordic Myeloma Study Group: Early response predicts thalidomide efficiency in patients with advanced multiple myeloma. Br J Haematol 2004; 125: 149-155.
39. Gulbrandsen N, Hjermstad M, Wisløff F for the Nordic Myeloma Study Group: Interpretation of quality of life scores in multiple myeloma by comparison with a reference population and assessment of the clinical impertance of score differences. Eur J Haematol 2004; 72: 172-180.
Rekvirering